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Height, adiposity and hormonal cardiovascular risk markers
in childhood: how to partition the associations?
JCK Wells1 and TJ Cole2
OBJECTIVE: Obesity is associated with rapid growth during childhood. There is uncertainty over how to adjust for body size, when
using adiposity as a proxy for cardiovascular risk. We studied associations of height, body composition (by dual-energy X-ray
absorptiometry) and cardiovascular risk markers (insulin resistance (IR), leptin) in children.
METHODS: Using partial correlations in 172 children aged 7–12 years, we investigated associations of (a) fat mass with IR or leptin,
adjusting for height or lean mass, and (b) height or lean mass with IR or leptin, adjusting for fat mass. Analyses were conducted
both cross-sectionally at each age, and for changes between 7 and 12 years.
RESULTS: Height, fat mass, lean mass, IR and leptin were all inter-correlated at all ages. Although fat mass was strongly associated
with IR and leptin, height was independently negatively associated with leptin (whole sample, adjusting for age: boys r=− 0.12,
girls r=− 0.13; Po0.001). Independent of adiposity, height was also associated with insulin IR (whole sample, adjusting for age:
boys r= 0.11, girls r= 0.20; Po0.001). When analysed by year of age, these associations tended to remain signiﬁcant at older ages.
Change in height from 7 to 12 years was also associated with change in IR (boys: r= 0.18, Po0.05; girls: r= 0.34, Po0.01),
independently of change in adiposity, with similar ﬁndings for lean mass.
CONCLUSIONS: During childhood, markers of cardiovascular risk have a complex proﬁle, associated with growth as well as fat
accumulation. Taller and faster-growing children have elevated risk markers, independently of their adiposity. These ﬁndings have
implications for the interpretation of pediatric indices of adiposity that aim to adjust for body size. Adiposity indices that perform
best at summarizing metabolic risk may not be those that perform best at understanding the developmental aetiology of risk.
International Journal of Obesity (2014) 38, 930–935; doi:10.1038/ijo.2014.24
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INTRODUCTION
Obesity is now well established to elevate the risk of chronic
degenerative diseases, including type 2 diabetes, hypertension,
cardiovascular disease (CVD) and some cancers.1,2 Although the
main effects of these diseases are experienced in later life,
childhood obesity appears to increase both short- and long-term
health risks.3–5 Monitoring of nutritional status during childhood
may potentially contribute to the reduction of these risks.
To address this issue, epidemiological studies have researched
both the factors that predispose to childhood obesity, and the
proﬁle of CVD risk accumulation over time. In this context, the
most widely studied index of nutritional status has been body
mass index (BMI).6–8 However, BMI does not provide information
on the relative proportions of fat and lean components in weight,9
hence, there is also interest in studying the accretion of fat and
lean tissue through childhood, and exploring their association
with the development of risk.10–12
The primary body composition outcomes investigated when
‘going beyond’ BMI are fat mass and lean mass (used here
synonymously with fat-free mass). However, it has long been
recognized that such data require some form of correction for
body size.13–15 Individuals who have grown faster or for longer are
expected to have greater absolute tissue masses, hence, size
adjustment is required to assess whether a given individual is
fatter or just larger. Whereas BMI adjusts weight for height, body
composition data have conventionally been expressed in the
format of ‘percentage fat’ (%fat), which describes the proportion
of fat in weight.13
The use of %fat as an index of adiposity presents two problems,
which remain poorly recognized. The ﬁrst issue is that this
approach directs undue attention to fat at the expense of lean.
This is unfortunate, as while excess fat is associated with poorer
health, variability in lean mass also contributes to the metabolic
proﬁle.16–18 The second issue is that %fat is statistically proble-
matic, as fat mass, when divided by weight, is present in both
numerator and denominator.19,20 As absolute fat mass increases,
%fat rises increasingly slowly, eventually trending towards an
asymptote at around 60% fat. In obese individuals, even large
gains or losses in adipose tissue mass may induce only small
changes in %fat. For example, if a person weighing 100 kg and
comprising 50% fat gains 10 kg of fat, the 20% increase in
absolute fat mass seems very modest when expressed as a change
in %fat, from 50 to 54.5%. Furthermore, high %fat values may
reﬂect high adiposity and/or low lean mass.19 The proportion of
fat in weight is therefore not an index of adiposity that is
independent of body size.
In adults, many researchers resolve this problem by splitting
BMI into two components, the lean mass index (LMI: lean mass/
height-squared) and the fat mass index (FMI: fat mass/height-
squared), each expressed in the same kgm−2 units as BMI. This
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approach, developed by Van Itallie et al.,14 has two beneﬁts: it
adjusts tissue masses for an independent component of body size,
while also keeping fat and lean outcomes separate. When this
approach is adopted in children, however, an additional statistical
issue becomes relevant.
BMI is calculated as weight/height-squared because this
statistical adjustment has been found to generate an index of
weight that is broadly independent of height. In some children’s
age groups, however, BMI may remain correlated with height.21,22
This could suggest that taller children are heavier even after
standardizing for height, or it could indicate that statistical
adjustment using the square of height is incompletely effective.
Each of these arguments has been made.19,23 The issue becomes
even more important if body composition is considered. Whereas
lean mass tends to scale with height-squared in childhood as in
adulthood,19,20,24 the power (n) to which height must be raised to
generate an index fat mass/heightn that is independent of height
approaches 5 or 6 in childhood,19 although it may also vary with
age. Fat mass index therefore remains correlated with height, that
is, taller children have greater adiposity using this approach.19,23
Recently, this dilemma received attention in analyses of the
EarlyBird cohort of children in Plymouth, UK, where data have
been collected at sequential time points on each of body size,
body composition and metabolic risk.25 These data allow
investigation of how body composition data might best be
expressed, in order to index CVD risk. In a recent publication on
this cohort, Metcalfe et al.25 reported that BMI or FMI had stronger
associations with leptin and insulin resistance (IR) than did indices
of weight or fat mass that adjusted completely for height
variability. They therefore proposed that height-normalized
indices were not the optimal approach for expressing adiposity
data. Instead, they argued that it is more appropriate to accept
that taller children are fatter, and that it does not help to use
statistical adjustments to hide this association.
In an invited commentary, we suggested that it may still be
helpful to try to disentangle associations of size and adiposity with
CVD risk, as each exposure may provide different information
about the aetiological development of risk.26 If BMI indexes risk,
but also remains positively correlated with height, then it appears
that some of this metabolic risk derives from height and growth
trajectory, independent of the risk deriving from adiposity.
As yet, however, the independent respective associations of fat
and height with indicators of cardiometabolic risk have not been
clearly determined. To enable investigation of this issue, Metcalfe
et al.25 made their data available to us. In this paper, we therefore
explore the independent associations of body size and body
composition with CVD risk in the EarlyBird cohort. The aim was to
gain greater insight into how these different exposures interact in
accounting for CVD risk, and hence to improve understanding of
what analyses may be done in future studies and how data may
best be expressed.
MATERIALS AND METHODS
Data were available annually from 7 to 12 years for 152 boys and 120 girls,
with a small loss of sample size (~15 boys, ~ 20 girls, varying by trait) over the
study period (see Table 1). The traits examined here were weight and height,
fat mass and lean mass, measured by dual-energy X-ray absorptiometry, and
fasting blood concentrations of insulin and leptin, two markers of CVD risk.
The insulin data were obtained through a validated approach, HOMA2-IR,
and represent a marker of peripheral IR. The details of the study design and
data collection have been described previously.25
Analyses
Preliminary analyses showed that fat mass, leptin and IR were
right-skewed, hence these variables were natural log-transformed to
achieve normality. All subsequent analyses were conducted on these
log-transformed values. All analyses were also conducted separately for
boys and girls.
Crude Pearson’s correlations were calculated to establish associations of
height with body composition, leptin and IR and also of fat mass and lean
mass with leptin and IR. These correlations were ﬁrst calculated for each
age group separately, and then for all data combined, partialling out the
effect of age. We also tested whether the sexes showed different
associations between height and leptin or insulin resistance, by including
a sex-interaction term.
Partial correlations were then calculated to establish the association of
fat with CVD risk adjusting for height, and of height with CVD risk adjusting
for fat. A similar approach was then used for body composition to establish
the association of fat mass with CVD risk adjusting for lean, and of lean
mass with CVD risk adjusting for fat. As BMI remains the index of adiposity
most commonly used in large epidemiological studies, we also calculated
the associations of height and lean mass with CVD risk, partialling out the
effect of BMI. Again, these correlations were ﬁrst calculated for each
separate age group and then for all age groups combined, partialling out
the effect of age.
We then calculated the change over time in each variable, as the
difference between the 7-year and 12-year values. These changes are
termed Δ, for example Δ fat refers to the increase in fat mass between 7
and 12 years. These changes were calculated from the log-transformed
start and end values for fat mass, leptin and IR. We ﬁrst tested whether
baseline leptin and IR were correlated with Δ height, Δ lean or Δ fat. We
then calculated partial correlations to assess associations of Δ fat with CVD
risk adjusting for Δ height or Δ lean, or of Δ height or Δ lean with Δ CVD
risk adjusting for Δ fat.
RESULTS
Descriptive data on the cohort have been given previously.25
Height was signiﬁcantly positively correlated with weight, BMI, fat
and lean masses, leptin and IR at all ages in both sexes (Table 1).
Thus, at any age, taller children have greater BMI and absolute
tissue masses, and greater circulating levels of leptin and IR. In the
whole sample, there were sex interactions in the association of
leptin and IR with height, indicating that the correlation
coefﬁcients were signiﬁcantly greater in girls than in boys (leptin:
Po0.001; IR: Po0.02). Supplementary Table S1 further shows that
fat mass and lean mass were both positively associated with leptin
and IR at all ages, and signiﬁcantly so at most ages.
Figure 1 summarizes the age-adjusted correlations of the three
Table 1. Crude correlations of height with indices of weight, body
composition and metabolic risk








7 152 0.81 0.34 0.59 0.87 0.32 0.19*
8 149 0.80 0.41 0.55 0.82 0.38 0.21*
9 138 0.81 0.47 0.61 0.83 0.34 0.36
10 140 0.80 0.50 0.62 0.81 0.43 0.41
11 134 0.77 0.46 0.60 0.81 0.31 0.21*
12 135 0.75 0.43 0.49 0.81 0.32 0.31
All adj. age 751 0.73 0.42 0.58 0.84 0.35 0.26
Girls
Visit
7 120 0.80 0.42 0.62 0.88 0.47 0.36
8 102 0.80 0.49 0.65 0.89 0.44 0.44
9 110 0.79 0.49 0.63 0.88 0.42 0.37
10 110 0.78 0.51 0.62 0.87 0.48 0.51
11 95 0.74 0.47 0.55 0.82 0.43 0.46
12 97 0.75 0.49 0.62 0.84 0.53 0.49
All adj. age 574 0.75 0.49 0.60 0.84 0.44 0.41
Abbreviation: BMI, body mass index. Fat mass, leptin and insulin resistance
are natural log-transformed. All adj. age—correlation in whole sample,
partialling out the effect of age. All correlations are signiﬁcant Po0.001
except *Po0.025.
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components of body size and composition (height, lean mass and
fat mass) with the two metabolic outcomes (leptin and IR). All
associations were highly signiﬁcant in both sexes, Po0.0001.
Table 2 shows that at all ages, fat mass adjusted for height was
correlated with both leptin and IR. In addition, height adjusted for
fat mass was inversely associated with leptin. In boys, these
correlations were signiﬁcant at 7, 11 and 12 years and in the age-
adjusted whole sample, while in girls, the correlations were
signiﬁcant at 8 and 10 years and in the age-adjusted whole
sample. In girls but not boys, height adjusted for fat mass was
positively associated with IR at 10 and 12 years. Table 2 also shows
the associations of height with IR and leptin, partialling out the
index of adiposity most widely used in clinical practice and
research studies, BMI. Height shows independent associations
with IR in both sexes, with the associations stronger at older ages.
There is only weak evidence of an association of height with IR
after adjustment for fat, and this association is positive, whereas
that of height and leptin adjusted for fat mass is negative.
Table 3 shows that at all ages, fat mass adjusted for lean mass
was correlated with leptin and IR. In boys at 11 and 12 years, and
in girls at 8, 10 and 11 years, lean mass adjusted for fat mass was
inversely associated with leptin. In girls aged 11 and 12 years, lean
mass adjusted for fat mass was positively associated with IR.
Table 4a shows that baseline leptin and IR were not associated
with Δ height in either sex. Baseline leptin was directly associated
with Δ lean in girls, and inversely associated with Δ fat in both
sexes. In girls, baseline IR was directly associated with Δ lean, and
inversely associated with Δ fat. Table 4b also shows correlations
for changes (Δ) in the variables from 7 to 12 years. Δ BMI was
positively associated with changes in all other traits. Δ height was
positively associated with Δ lean and Δ fat, showing that children
growing faster in height gained more fat and more lean. However,
Δ lean and Δ fat were not correlated. Both Δ height and Δ lean
were associated with Δ IR but not Δ leptin, whereas Δ fat was
associated with both Δ leptin and Δ IR. Furthermore, Δ leptin was
positively associated with Δ IR.
Table 5 shows partial correlations, adjusting the associations
between Δ fat and Δ cardiovascular risk markers for Δ height or Δ
lean mass, and vice versa. Adjusting for Δ height, Δ fat was
positively associated with Δ IR and Δ leptin. Similarly, adjusting for
Δ lean, Δ fat was positively associated with both Δ leptin and Δ
IR. Thus, independently of growth in height or lean mass,
increasing adiposity was associated with increased CVD risk.
Adjusting for Δ fat, Δ height was associated with Δ IR but not with
Δ leptin, while Δ lean was associated with Δ IR in both sexes and
showed a borderline-signiﬁcant association with Δ leptin in girls
only. These results indicate that independent of increases in
adiposity, growth in height or lean mass was associated with
increasing IR.
DISCUSSION
These data indicate that taller children have greater absolute fat
mass and leptin and IR, as described previously in the same
cohort, with our analyses demonstrating that the crude associa-
tion of height with leptin and IR is stronger in girls than in boys.25
However, height and lean mass also show associations with each
of fat mass, leptin and IR. Disentangling their respective
independent associations may help understand how best to
express data on body composition in order to index and interpret
metabolic risk.
Metcalf et al.25 argued that normalizing weight or fat mass for
height ‘obfuscates’, and that the elevated metabolic risk of taller
fatter children would be missed using this approach. We argued
that part of the elevated risk in taller children might derive from
their height, independently of their high adiposity, and that these
different sources of risk are important to know about.26
Consistent with our predictions, our cross-sectional analyses
show that while much of the variability in CVD risk can be
attributed to adiposity, height also has associations with each of
leptin (both sexes) and IR (girls only), that are independent of
adiposity. From 11 years in boys, and at 8 and 11 years in girls,
taller children have lower leptin, and taller girls at 10 and 12 years
have greater IR. These trends are also signiﬁcant in the whole
sample, adjusting for age. These ﬁndings are broadly replicated for
lean mass, such that adjusting for adiposity, older children with
greater levels of lean mass have lower leptin, whereas older girls
with more lean mass have greater IR.
The strong association of fat mass with leptin at every age, even
after adjusting for height, is consistent with the notion that leptin



















Figure 1. Age-adjusted correlations of height, lean mass or fat mass
with leptin and insulin in the entire sample, presented separately for
males (M) and females (F). Fat mass, insulin and leptin were natural
log-transformed. All correlations Po0.0001.
Table 2. Partial correlations for associations of leptin and insulin with
















7 0.68** − 0.20** 0.05 0.28** − 0.02 0.05
8 0.61** − 0.07 0.12 0.41** − 0.10 0.07
9 0.53** − 0.02 0.09 0.32** 0.12 0.21*
10 0.66** − 0.04 0.12 0.41** 0.13 0.23*
11 0.82** − 0.36** − 0.04 0.40** − 0.07 0.04
12 0.84** − 0.29** 0.03 0.41** 0.04 0.16
All adj. age 0.68** − 0.12** 0.09* 0.37** 0.01 0.11**
Girls
Visit
7 0.70** − 0.02 0.21* 0.47** − 0.00 0.14
8 0.79** − 0.19 ** 0.10 0.38** 0.15 0.25*
9 0.74** − 0.27 0.08 0.38** 0.02 0.15
10 0.76** − 0.06 0.20* 0.43** 0.20* 0.32**
11 0.88** − 0.34** 0.04 0.55** 0.13 0.22*
12 0.88** − 0.07 0.19 0.41** 0.22 * 0.28**
All adj. age 0.78** − 0.13** 0.12* 0.52** 0.11* 0.20**
Abbreviation: BMI, body mass index. Fat mass, leptin and insulin are natural
log-transformed. All adj. age—correlation in whole sample, partialling out
the effect of age . **Po0.001; *Po0.05.
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with lean mass or height, which only emerged after adjusting for
adiposity, suggests that leptin might further differentiate between
fat and lean tissues, such that for a given quantity of fat mass,
those with greater lean mass produce less leptin. Our longitudinal
analyses show that baseline leptin is associated with the
subsequent increase in lean mass, signiﬁcant in girls only.
However, baseline leptin did not predict increases in height, and
the main longitudinal associations were a positive correlation
between change in fat and change in leptin, indicating that
children increasing in adiposity secrete more leptin. Thus, leptin
may reﬂect the ratio of fat to lean as well as energy stores per se,
without driving subsequent tissue accretion patterns over time.
One possibility is that leptin acts as a permissive signal for
puberty,29 such that children progressing faster through puberty
are both taller and also have lower leptin, as the energy is already
being invested in the pubertal growth spurt.
In longitudinal analyses, change in adiposity was strongly
associated with greater change in IR, but the causal direction of
this association remains unclear. It may derive either through IR
driving the accumulation of adipose tissue,30,31 or through weight
gain and a lipogenic diet favouring IR to protect tissues against
nutrient overload.32,33 Regardless of the causal direction of the
association, it is clear that increases in adiposity are the dominant
factor correlating with IR in this sample, however, gains in height
and lean tissue also showed independent associations with
increases in IR.
Although IR was associated in cross-sectional analyses with
height and lean mass at every age in crude analyses, these
associations disappeared once adjusted for adiposity, except in
older girls. Thus, we assume that younger taller children have
greater IR because they are also fatter, whereas older taller girls
have greater IR independent of their fatness. Higher IR at 7 years
predicted greater gains in lean mass in girls, but not greater
increase in height, whereas the increase in IR between 7 and 12
years was correlated with increases in each of height, lean mass
and fat mass. Although it remains difﬁcult to interpret these data
in terms of causality, our analyses demonstrate that growing taller
and depositing more lean tissue are associated with increasing IR
independent of adiposity, hence, fasting insulin by HOMA acts as a
marker of growth as well as adiposity.
A limitation of our study is that we were only able to analyse
two markers of cardiovascular risk, namely leptin and IR. We
focused on these two outcomes precisely because they are
simultaneously regulators of growth and body composition, while
also predictive of future chronic disease risk. We cannot be sure
that other cardiovascular risk markers would show similar
associations. However, in a previous analysis of the ALSPAC
cohort at age 9 years, we showed independent associations of
height, lean mass and adiposity with blood pressure.18 Further
work will be required to reveal how general the association of
height and cardiovascular risk is in children. We also note that in
adults, short stature is associated with greater cardiovascular
risk.34,35 This contrast may arise as taller children may be those
growing faster during childhood, and not necessarily those who
will be tallest in adulthood.
A second limitation was the sample size and the conducting of
many statistical tests, which increases the possibility of reporting
signiﬁcant associations that actually arose through chance. Our
Table 3. Partial correlations for associations of leptin and insulin with
fat adjusted for lean, and with lean adjusted for fat
Leptin Insulin
Fat adj. lean Lean adj. fat Fat adj. lean Lean adj. fat
Boys
Visit
7 0.63** − 0.10 0.18 * 0.13
8 0.60** − 0.01 0.42** − 0.11
9 0.57** − 0.11 0.36** 0.05
10 0.67** − 0.04 0.43** 0.08
11 0.81** − 0.28* 0.42** − 0.10
12 0.86** − 0.41** 0.41** 0.05
All adj. age 0.68** − 0.13** 0.38** − 0.01
Girls
Visit
7 0.69** − 0.04 0.44** 0.02
8 0.80** − 0.23* 0.36** 0.20
9 0.70** − 0.12 0.34* 0.03
10 0.77** − 0.20* 0.40** 0.16
11 0.87** − 0.32* 0.48** 0.25*
12 0.86** − 0.03 0.34* 0.29**
All adj. age 0.78** − 0.13** 0.40** 0.17**
Fat mass, leptin and insulin are natural log-transformed. All adj. age—
correlation in whole sample, partialling out the effect of age . **Po0.0001;
*Po0.05.
Table 4a. Longitudinal associations between body composition and
metabolic risk from 7 to 12 years. Correlations between baseline leptin
or insulin and change in size or body composition between 7 and 12
years
Δ Height Δ Lean Δ Fat
Boys Girls Boys Girls Boys Girls
Leptin 7 years 0.06 0.15 0.15 0.40** − 0.21** − 0.27**
Insulin 7 years − 0.03 0.10 0.02 0.27* 0.06 − 0.35**
Fat mass, leptin and insulin are natural log-transformed. Δ= change
between 7 and 12 years . **Po0.01; *Po0.05.
Table 4b. Longitudinal associations between body composition and metabolic risk from 7 to 12 years. Correlations of change in size, body
composition and metabolic risk from 7 to 12 years
Δ BMI Δ Lean Δ Fat Δ Leptin Δ Insulin
resistance
Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls
Δ Height 0.37# 0.46# 0.77# 0.80# 0.27# 0.20* 0.12 0.17 0.23** 0.36#
Δ BMI — — 0.46# 0.58# 0.81# 0.70# 0.67# 0.57# 0.38# 0.47#
Δ Lean — — — — 0.15 0.08 0.04 0.18 0.29# 0.39#
Δ Fat — — — — — — 0.68# 0.56# 0.25** 0.41#
Δ Leptin — — — — — — — — 0.44# 0.50#
Abbreviation: BMI, body mass index. Fat mass, insulin and leptin are natural log-transformed . #Po0.001; **Po0.01; *Po0.05.
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ﬁndings should therefore be conﬁrmed using larger data sets,
however, we note that our previous study, identifying indepen-
dent associations of height and adiposity with blood pressure, was
conducted in >6500 children.18
Overall, our analyses indicate complexity in the associations
between body size, growth rate, body composition and metabolic
risk. Further work will need to be undertaken to tease out the
effects in greater detail, but it is already clear from these data that
associations of height or lean mass with CVD risk are not fully
explained by their respective associations with adiposity. Rather,
tall height and high lean mass are associated with CVD risk,
independent of adiposity, and these associations evolve over time.
As both height and adiposity correlate with elevated metabolic
risk, some indices such as BMI or FMI incorporate both of these
sources of risk without distinguishing between them.26 Table 2
shows that height retains associations with IR, after adjusting for
BMI, but this information is lost when using BMI as an index of
adiposity, as the rationale of the index is to ‘remove any effect of
height’. The same is true for FMI, which is generally treated only as
an index of adiposity.
Previously, we noted that fat mass divided by height6 was
independent of height in children aged 8 years.19 Using such an
index, it is possible to assess the proportion of risk that derives
from adiposity, independent of that deriving from height. This
partitioning of risk has some beneﬁts, because the factors
(environmental or genetic) that account for variability in adiposity
may not be identical with those that account for variability in
growth.26 For example, linear growth appears most sensitive to
environmental factors during fetal life and infancy,36,37 and many
studies have associated early catch-up growth with subsequent
adiposity.12,38–40 However, adiposity may be more sensitive to
behaviours such as diet composition and physical activity
behaviour throughout childhood.41–44
In general, the management of obesity favours loss of fat, but
not a reduction in growth,45 hence, it is possible that the
treatment of taller children might be inherently less successful at
reducing metabolic risk than the treatment of shorter children. In
Swedish adults, for example, the metabolic penalty (elevated
blood pressure) for low birth weight was greater in individuals
with both high BMI and greater height, and the highest blood
pressures were found in those born small who were both obese
and tall in adulthood.46
However, the partitioning of CVD risk into different components
is also artiﬁcial, because of the complex ways in which growth in
height and adiposity appear to be connected, in part by the very
hormones that are used as markers of metabolic risk. As the
hormones that index CVD risk also contribute to the regulation or
growth and tissue deposition, BMI and FMI may be clinically useful
ways to summarize metabolic risk, but not necessarily the best
way to understand its aetiology.
Nevertheless, we suggest that such partitioning may be
particularly helpful when addressing children approaching and
undergoing puberty. At this time, elevations of CVD risk may relate
in part to the faster tempo of growth during this period, and it
may be valuable to quantify the component of risk attributable to
adiposity, potentially more amenable to management. A novel
statistical approach (SITAR)47 that can disentangle size, growth
tempo and velocity might clarify these associations, for example,
by adjusting the growth trajectory for the timing of puberty. Each
approach therefore has some merits: BMI or FMI give a global
index of CVD risk, integrating effects of growth and adiposity,
whereas approaches using multiple regression analysis (simply
entering terms separately) or speciﬁc indices (for example, fat
normalized for height, or regression residuals) may tease out the
contribution of growth versus adiposity to CVD risk, and clarify the
opportunities for intervention.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We are grateful to Terence Wilkin and Brad Metcalf on behalf of the EarlyBird study
for making their data available to us.
REFERENCES
1 Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective.
Cancer Treat Res 2014; 159: 21–33.
2 Lewis GF. Devastating metabolic consequences of a life of plenty: focus on the
dyslipidemia of overnutrition. Clin Invest Med 2013; 36: E242.
3 Power C, Lake JK, Cole TJ. Measurement and long-term health risks of child
and adolescent fatness. Int J Obes 1997; 21: 507–526.
4 Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and
adolescence on morbidity and premature mortality in adulthood:
systematic review. Int J Obes 2011; 35: 891–898.
5 Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart Let al. Health
consequences of obesity. Arch Dis Child 2003; 88: 748–752.
6 Goodman E, Dolan LM, Morrison JA, Daniels SR. Factor analysis of clustered
cardiovascular risks in adolescence: obesity is the predominant correlate of risk
among youth. Circulation 2005; 111: 1970–1977.
7 Janssen I, Katzmarzyk PT, Srinivasan SR, Chen W, Malina RM, Bouchard C et al.
Utility of childhood BMI in the prediction of adulthood disease: comparison of
national and international references. Obes Res 2005; 13: 1106–1115.
8 Blüher S, Molz E, Wiegand S, Otto KP, Sergeyev E, Tuschy Set al. Body mass index,
waist circumference, and waist-to-height ratio as predictors of cardiometabolic
risk in childhood obesity depending on pubertal development. J Clin Endocrinol
Metab 2013; 98: 3384–3393.
9 Wells JC. A Hattori chart analysis of body mass index in infants and children.
Int J Obes 2000; 24: 325–329.
10 Ibáñez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and
insulin resistance after catch-up weight gain in small-for-gestational-age children.
J Clin Endocrinol Metab 2006; 91: 2153–2158.
11 Lawlor DA, Benﬁeld L, Logue J, Tilling K, Howe LD, Fraser A et al. Association
between general and central adiposity in childhood, and change in these, with
cardiovascular risk factors in adolescence: prospective cohort study. BMJ 2010;
341: c6224.
12 Dulloo AG, Jacquet J, Seydoux J, Montani JP. The thrifty 'catch-up fat' phenotype:
its impact on insulin sensitivity during growth trajectories to obesity and
metabolic syndrome. Int J Obes 2006; 30 (Suppl 4): S23–S35.
13 Pietrobelli A, Faith MS, Allison DB, Gallagher D, Chiumello G, Heymsﬁeld SB. Body
mass index as a measure of adiposity among children and adolescents:
a validation study. J Pediatr 1998; 132: 204–210.
14 Van Itallie TB, Yang MU, Heymsﬁeld SB, Funk RC, Boileau RA. Height-normalized
indices of the body's fat-free mass and fat mass: potentially useful indicators of
nutritional status. Am J Clin Nutr 1990; 52: 953–959.
Table 5. Partial correlations of change in size, body composition and
metabolic risk from 7 to 12 years
Δ Leptin adj. Δ Height Δ Insulin adj. Δ Height
Boys Girls Boys Girls
Δ Fat 0.68# 0.55# 0.20* 0.36#
Δ Leptin adj. Δ Fat Δ Insulin adj. Δ Fat
Boys Girls Boys Girls
Δ Height − 0.09 0.09 0.20* 0.31**
Δ Leptin adj. Δ Lean Δ Insulin adj. Δ Lean
Boys Girls Boys Girls
Δ Fat 0.68# 0.57# 0.22* 0.41#
Δ Leptin adj. Δ Fat Δ Insulin adj. Δ Fat
Boys Girls Boys Girls
Δ Lean −0.08 0.19 0.21* 0.39#
Fat mass, insulin and leptin are natural log-transformed. Δ= change
between 7 and 12 years. #Po0.001; **Po0.01; *Po0.05.
Height, adiposity and hormonal cardiovascular risk markers in childhood
JCK Wells and TJ Cole
934
International Journal of Obesity (2014) 930 – 935 © 2014 Macmillan Publishers Limited
15 Wells JC. A critique of the expression of paediatric body composition data. Arch
Dis Child 2001; 85: 67–72.
16 Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr 2000; 4
(Suppl 3): S40–S47.
17 Unni US, Ramakrishnan G, Raj T, Kishore RP, Thomas T, Vaz Met al. Muscle mass
and functional correlates of insulin sensitivity in lean young Indian men. Eur J Clin
Nutr 2009; 63: 1206–1212.
18 Grijalva-Eternod CS, Lawlor DA, Wells JC. Testing a capacity-load model for
hypertension: disentangling early and late growth effects on childhood blood
pressure in a prospective birth cohort. PLoS One 2013; 8: e56078.
19 Wells JC, Cole TJ. ALSPAC study team Adjustment of fat-free mass and fat mass for
height in children aged 8 y. Int J Obes Relat Metab Disord 2002; 26: 947–952.
20 Wells JC, Victora CG. Indices of whole-body and central adiposity for evaluating
the metabolic load of obesity. Int J Obes 2005; 29: 483–489.
21 Cole TJ. Weight/heightp compared to weight/height2 for assessing adiposity in
childhood: inﬂuence of age and bone age on p during puberty. Ann Hum Biol
1986; 13: 433–451.
22 Cole TJ, Henson GL, Tremble JM. Colley NV.Birthweight for length: ponderal index,
body mass index or Benn index? Ann Hum Biol 1997; 24: 289–298.
23 Cole, TJ. Weight-stature indices to measure underweight, over- weight and
obesity. Anthropometric Assessment of Nutritional Status. Wiley Liss: New York,
1991; 83–111.
24 Heymsﬁeld SB, Gallagher D, Mayer L, Beetsch J, Pietrobelli A. Scaling of human
body composition to stature: new insights into body mass index. Am J Clin Nutr
2007; 86: 82–91.
25 Metcalf BS, Hosking J, Frémeaux AE, Jeffery AN, Voss LD, Wilkin TJ. BMI was right
all along: taller children really are fatter (implications of making childhood BMI
independent of height) EarlyBird 48. Int J Obes 2011; 35: 541–547.
26 Wells JC, Cole TJ. Disentangling the size and adiposity components of obesity. Int
J Obes 2011; 35: 548–549.
27 Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;
967: 379–388.
28 Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Müller Jet al. Plasma leptin
levels in healthy children and adolescents: dependence on body mass index,
body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab
1997; 82: 2904–2910.
29 Lustig RH. Childhood obesity: behavioral aberration or biochemical drive?
Reinterpreting the First Law of Thermodynamics. Nat Clin Pract Endocrinol Metab
2006; 2: 447–458.
30 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome respon-
sible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic
cardiovascular disease. Diabetes Care 1991; 14: 173–194.
31 Catalano PM, Presley L, Minium J, Hauguel-de Mouzon S. Fetuses of obese
mothers develop insulin resistance in utero. Diabetes Care 2009; 32: 1076–1080.
32 Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ et al.
Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci
USA 2009; 106: 17787–17792.
33 Lustig RH. Which comes ﬁrst? The obesity or the insulin? The behavior or the
biochemistry?. J Pediatr 2008; 152: 601–602.
34 Waaler HT. Height, weight and mortality. The Norwegian experience. Acta Med
Scand Suppl 1984; 679: 1–56.
35 Davey Smith G, Hart C, Upton M, Hole D, Gillis C, Watt G et al. Height and risk of
death among men and women: aetiological implications of associations with
cardiorespiratory disease and cancer mortality. J Epidemiol Community Health
2000; 54: 97–103.
36 Smith DW, Truog W, Rogers JE, Greitzer LJ, Skinner AL, McCann JJ et al. Shifting
linear growth during infancy: illustration of genetic factors in growth from fetal
life through infancy. J Pediatr 1976; 89: 225–230.
37 Wells JC, Hallal PC, Wright A, Singhal A, Victora CG. Fetal, infant and childhood
growth: relationships with body composition in Brazilian boys aged 9 years. Int J
Obes 2005; 29: 1192–1198.
38 Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between
postnatal catch-up growth and obesity in childhood: prospective cohort study.
BMJ 2000; 320: 967–971.
39 Modi N, Thomas EL, Harrington TA, Uthaya S, Doré CJ, Bell JD. Determinants of
adiposity during preweaning postnatal growth in appropriately grown and
growth-restricted term infants. Pediatr Res 2006; 60: 345–348.
40 Chomtho S, Wells JC, Williams JE, Davies PS, Lucas A, Fewtrell MS. Infant growth
and later body composition: evidence from the 4-component model. Am J Clin
Nutr 2008; 87: 1776–1784.
41 Fiorito LM, Marini M, Francis LA, Smiciklas-Wright H, Birch LL. Beverage intake of
girls at age 5 y predicts adiposity and weight status in childhood and adoles-
cence. Am J Clin Nutr 2009; 90: 935–942.
42 Ambrosini GL, Emmett PM, Northstone K, Howe LD, Tilling K, Jebb SA.
Identiﬁcation of a dietary pattern prospectively associated with increased
adiposity during childhood and adolescence. Int J Obes 2012; 36:
1299–1305.
43 Staiano AE, Harrington DM, Broyles ST, Gupta AK, Katzmarzyk PT. Television,
adiposity, and cardiometabolic risk in children and adolescents. Am J Prev Med
2013; 44: 40–47.
44 Rennie KL, Livingstone MB, Wells JC, McGloin A, Coward WA, Prentice AM et al.
Association of physical activity with body-composition indexes in children aged
6-8 y at varied risk of obesity. Am J Clin Nutr 2005; 82: 13–20.
45 Barlow SE, Dietz WH. Obesity evaluation and treatment: expert committee
recommendations. The Maternal and Child Health Bureau, Health Resources and
Services Administration and the Department of Health and Human Services.
Pediatrics 1998; 102: E29.
46 Leon DA, Koupilova I, Lithell HO, Berglund L, Mohsen R, Vagero D et al. Failure to
realise growth potential in utero and adult obesity in relation to blood pressure in
50 year old Swedish men. BMJ 1996; 312: 401–406.
47 Cole TJ, Donaldson MD, Ben-Shlomo Y. SITAR - a useful instrument for growth
curve analysis. Int J Epidemiol 2010; 39: 1558–1566.
This work is licensed under a Creative Commons Attribution 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by/3.0/
Supplementary Information accompanies this paper on International Journal of Obesity website (http://www.nature.com/ijo)
Height, adiposity and hormonal cardiovascular risk markers in childhood
JCK Wells and TJ Cole
935
© 2014 Macmillan Publishers Limited International Journal of Obesity (2014) 930 – 935
